Resources

People who inject drugs (PWID) are a key population for the elimination of hepatitis C in Europe, and increasing their access to HCV testing and care is a goal in European and national hepatitis C policies. Despite this, HCV testing remains low among people who inject drugs and effective approaches to promote testing as the first element of a cascade of care are particularly needed.

Objective: to discuss the results of the report Prison and drugs in Europe: current and future challenges Insights with key customers.

Designer drug is a structural or functional analog of a controlled substance that has been designed to mimic the pharmacological effects of the original drug, while avoiding classification as illegal and/or detection in standard drug tests.[1] Designer drugs include psychoactive substances that have been designated by the European Union as new psychoactive substances (NPS)[2] as well as analogs of performance-enhancing drugs such as designer s

Drug Abuse Problems in Youth/Students A Message By Drug Abuse Control Society GC Women University Faisalabad

The International Day against Drug Abuse and Illicit Trafficking, or World Drug Day, is marked on 26 June every year, to strengthen action and cooperation in achieving the goal of a world free of drug abuse.

Share Facts On Drugs, Save Lives The International Day against Drug Abuse and Illicit Trafficking, or World Drug Day, is marked on 26 June every year, to strengthen action and cooperation in achieving the goal of a world free of drug abuse.

ISSUP Chile invites you to participate in a webinar on evidence-based prevention: advances and challenges for Chile.

The webinar will take place on Wednesday, June 30, 2021 at 12:00 p.m. (Chile Time)

How has the COVID-19 pandemic affected drug use and supply? What drugs are causing the most concern today? What are the latest trends in drug production and trafficking?

ATOMIC is a free, evidence-based, mobile-learning application aimed at clinicians and other practitioners who want to improve their knowledge of the acute and chronic clinical harms of non-medical prescription drug use. ATOMIC is a response to increasing public health concern regarding the harms of non-medical prescription drug use.

This Primer is an introduction to Demand Reduction and Primary Prevention, aimed at policy makers and educators in the AOD space. It is written in accessible language to invite the investigator to better reflect on basic principles of best-practice for best health outcomes for our communities. 

Stigma is one of the biggest barriers people face when seeking care for substance use disorders. Designed for members of the law enforcement community, this webinar explored the relationship between substance use, the brain and mental health, and how stigma can be a barrier to accessing and receiving care.

Panelists also discussed the impact stigma has on people who use substances, their families and communities.
 

Since the early 2000s, adolescent drinking in Australia and in many high income countries has fallen dramatically. For example, among 14-17 year old Australians, the rate of risky drinking has fallen from 30% in 2001 to 9% in 2019. This seminar summarised a program of work looking to understand these trends, addressing the potential causes of these declines, the implications for adult drinking and harm and next steps for research.

Presented by Associate Professor Lexine Stapinski (the Matilda Centre) this webinar will lead to:

1. An understanding of typical patterns and issues relevant to the management of anxiety and alcohol use disorder comorbidity;

2. Introduction to an integrated cognitive behaviour therapy program that improves outcomes by concurrently addressing anxiety, alcohol use and the connections between them;